我院94例冠心病患者二级预防用药调查分析

Investigation and Analysis of Secondary Preventive Medication of 94 Cases of Coronary Heart Disease in Our Hospital

目的:了解我院冠心病(CHD)患者二级预防用药情况,为CHD的规范化治疗提供参考。方法:采用回顾性方法,对我院2009年7-10月心血管内科94例CHD患者的预防用药情况进行统计、分析。结果:我院CHD患者服用抗血小板药、β受体阻滞药、调脂药和血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体抑制剂(ARB)的比例分别为95.74%、52.13%、90.43%和61.70%;二联用药比例占26.60%,三联用药比例占42.55%,四联用药比例占30.85%。结论:抗血小板药和调脂药应用与CHD二级预防指南符合率较高,β受体阻滞药、ACEI和ARB应用与指南要求有较大差距。有效的治疗指南在临床实践中并没有得到很好的应用,因此还需加强CHD二级预防用药,缩小临床实践与指南的差距。

OBJECTIVE：To probe into the secondary preventive medication for the patients with coronary heart disease （CHD） in our hospital, and to offer reference for the standardized treatment of CHD. METHODS： By retrospective method, the preventive medication for 94 patients with CHD in cardiovascular medicine department of our hospital during Jul.-Oct. in 2009 was analyzed statistically. RESULTS： The percentages of patients who took antiplatelet drugs, β blocker, lipid-lowering drugs and ACEI or ARB were 95.74%, 52.13%, 90.43% and 61.70%. The percentages of patients who took two-drug, three-drug and four-drug were 26.60%, 42.55% and 30.85%. CONCLUSION： The application of antiplatelet drugs and lipid-lowering drugs is in line with secondary prevention guideline of CHD. The application of β blocker, ACEI and ARB keeps some pace with the requirements of prevention guideline. The guideline hadn’t been utilized fully, and we need to strengthen the secondary preventive medication for CHD to decrease the gap between clinical practice and guideline.